Anixa to present ovarian cancer CAR-T trial findings at ESMO
Anixa Biosciences said Dr. Robert Wenham will present its Phase 1 ovarian cancer CAR-T trial at the ESMO Immuno-Oncology & Advanced Therapies Congress in London on December 14, 2026. The Moffitt Cancer Center study has completed its fifth cohort without observed dose-limiting toxicities, and Anixa plans to move to a sixth cohort at 1x10⁸ CAR-positive cells/kg after safety verification. The company reported stable disease in the first patient at 90 days and said four patients had lived beyond one year, including one who exceeded two years.
Why it matters
The December presentation creates a dated opportunity for the company to disclose further clinical information on lira-cel. The planned sixth cohort would test a materially higher dose, but it remains subject to safety verification and the program is still in Phase 1.
Key facts
- 1Dr. Robert Wenham is scheduled to present the trial on December 14, 2026, during the ESMO Congress in London. prnewswire.com
- 2The fifth cohort used 1x10⁷ CAR-positive cells per kilogram after lymphodepletion. prnewswire.com
- 3Anixa anticipates a sixth cohort at 1x10⁸ CAR-positive cells/kg, compared with an initial dose of 1x10⁵ CAR-positive cells/kg. prnewswire.com
- 4The company reported no dose-limiting toxicities, stable disease in the first patient 90 days after treatment, and four patients surviving more than one year, including one beyond two years. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.